SGLT2 Inhibitors for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

SGLT2 Inhibitors for Health & Longevity

Created on 10/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

These once-daily oral prescription medications for type 2 diabetes, heart failure and kidney disease make the kidneys flush extra sugar and salt into the urine. In these patients, strong trial evidence shows fewer heart failure hospital stays, slower kidney decline and modestly longer survival. No trial has tested them in healthy people for longevity. The main risks are genital yeast infections and rare but dangerous blood acid build-up. (Full Review)

Protocol

Heart-and-kidney protection approach
Empagliflozin or dapagliflozin 10 mg once daily
Labeled dose and trial regimen; canagliflozin 100 mg as in CREDENCE
Off-label longevity approach
Untested in healthy adults
Human use borrows the labeled 10 mg dose
Time of day
Morning dosing
Empagliflozin labeled for the morning; limits nighttime urination
Time to effect
Outcome benefits
Roughly 1.5 to 4 years
Measured over trial follow-up
Blood pressure and weight
Weeks
Change over weeks of use
Urinary glucose loss
Within hours
Starts after the first dose

Benefits

Contraindications
  • Serious hypersensitivity to the drug (such as angioedema)
  • Type 1 diabetes
  • Pregnancy (second and third trimesters) and breastfeeding
  • eGFR below 20 mL/min/1.73 m² or dialysis when starting empagliflozin (not studied); glucose-lowering use below eGFR 30 (canagliflozin) or 45 (dapagliflozin)
  • Severe liver impairment (Child-Pugh class C) for canagliflozin
  • Uncorrected fluid loss (until corrected)
  • Caution: history of ketoacidosis, pancreatitis or pancreatic surgery, recurrent genital or urinary infections, active foot ulcers or prior amputation
    •
Key Interactions
  • Insulin and insulin secretagogues (insulin glargine, glipizide, glyburide): higher low blood sugar risk
  • Diuretics (furosemide, hydrochlorothiazide): fluid loss, low blood pressure
  • Lithium: may lower blood lithium
  • UGT enzyme inducers (rifampin, phenytoin): reduced canagliflozin exposure
  • Digoxin: higher exposure with canagliflozin
  • Renin-angiotensin system drugs (ramipril, losartan): additive blood pressure lowering, early eGFR dip
  • GLP-1 receptor agonists (semaglutide, tirzepatide): additive glucose, weight and blood pressure lowering
  • NSAIDs (ibuprofen, naproxen): acute kidney injury risk during dehydration or illness (theoretical)
  • Alcohol: abuse is a listed ketoacidosis precipitant
  • Urine glucose tests and 1,5-anhydroglucitol assay: unreliable results
  • Glucose-lowering supplements (berberine, chromium, cinnamon): additive glucose lowering (theoretical)
  • Blood pressure-lowering supplements (garlic extract, hibiscus, beetroot nitrate): additive blood pressure lowering (theoretical)
  • Herbal diuretics and high-dose caffeine (dandelion, horsetail): additive fluid loss (theoretical)
  • Exogenous ketones and MCT oil: additive ketosis may mask early ketoacidosis (theoretical)
  • Ketogenic diets and prolonged fasting: listed ketoacidosis precipitants
  • Surgery or procedures requiring prolonged fasting: ketoacidosis risk (withheld at least 3 days beforehand)
    •

Risk & Side Effects

  • High: Genital yeast infections; ketoacidosis; small rise in LDL cholesterol
    •
  • Medium: Low blood sugar with insulin or sulfonylureas; loss of muscle mass
    •
  • Low: Fluid loss and low blood pressure; lower-limb amputation; bone fracture; acute kidney injury; urinary tract infections; Fournier's gangrene; bladder cancer
    •
  • Speculative: Blunted insulin-sensitivity gains from exercise
    •

Monitoring

Marker Target Why
eGFR and creatinine Creatinine about 0.7–1.3 mg/dL (men), 0.6–1.1 mg/dL (women); eGFR: no established target, track change from own baseline Safety check: large falls change use
Blood beta-hydroxybutyrate Below 0.4 mmol/L Safety check: rising ketones with symptoms stop use
HbA1c 4.0–5.6% Expected to change: falls in diabetes
Hematocrit About 41–50% (men), 36–44% (women) Expected to change and safety check: rises on treatment
LDL cholesterol No established target for this intervention; track change from own baseline Expected to change: rises slightly
Serum uric acid About 3.5–7.2 mg/dL (men), 2.6–6.0 mg/dL (women) Expected to change: falls on treatment
Urine albumin-to-creatinine ratio No established target for this intervention; track change from own baseline Expected to change: falls in kidney disease
Blood pressure (home) No established target for this intervention; track change from own baseline Expected to change and safety check: falls; symptomatic lows change use

Cadence: Baseline panel before starting; eGFR and electrolytes at 2–4 weeks, then every 6–12 months; HbA1c, lipids, hematocrit and uric acid at 3 months, then every 6–12 months; blood ketones whenever symptoms suggest ketoacidosis; home blood pressure and weight weekly for the first month, then monthly

Qualitative Assessment

  • Genital itching, discharge or soreness (early yeast infection)
  • Urination frequency and nighttime waking
  • Thirst, dizziness on standing or unusual fatigue (fluid loss)
  • Nausea, vomiting, abdominal pain or breathlessness (possible ketoacidosis)
  • Exercise tolerance, strength and energy levels
  • Foot sores or slow-healing skin lesions
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.